Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Hemink Groep has been acquired by Gimv
Gimv has acquired a majority stake in Hemink, a Dutch specialist in real estate renovation and maintenance. This transaction marks a new chapter for Hemink, as it seeks to expand its position as a national leader in sustainable property services through its new partnership with Gimv.
Learn moreThe Providence Projects has been acquired by UKAT Group
Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.
Learn moreSt. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn more